Niaz Banaei

Niaz Banaei received his medical education from Stanford University and completed residency training in laboratory medicine at the University of California, San Francisco. He then completed a postdoctoral fellowship in infectious diseases at the New York University. He is currently an Associate Professor of Pathology and Medicine at Stanford University and is the Medical Director of the Clinical Microbiology Laboratory at Stanford Medical Center. In addition, he is the Director of Stanford Pathology Fellowship in Global Health Diagnostics. He serves on the board of advisors for the Center for Disease Control Tuberculosis Epidemiologic Studies Consortium II (TBESC). His research interests include (1) development, assessment, and improvement of novel infectious diseases diagnostics, (2) enhancing the quality of C. difficile diagnostic results, and (3) characterization of M. tuberculosis virulence determinants. He was the recipient of Kenneth L. Vosti Infectious Diseases and Stanford University clinical pathology junior faculty teaching awards. He has authored over sixty peer-reviewed journal articles and several book chapters.

Lucille Blumberg

Professor Lucille Blumberg is a deputy director at the National Institute for Communicable Diseases, a branch of the National Health Laboratory Service, and is based in Johannesburg, South Africa. She heads the Epidemiology Division, which includes the units for Outbreak Response, Travel and International Health, Epidemiology and Surveillance, as well as the Field Epidemiology and Laboratory Training programme. She is the medical consultant to the Special Pathogens Unit on rabies and Viral Haemorrhagic fevers.

Kalifa Bojang

Kalifa Bojang is the head of the paediatric department of the Royal Victoria Teaching Hospital and a Senior clinical scientist at the Medical Research Council Unit in The Gambia. Kalifa Bojang studied medicine at University of Zambia, qualifying in 1984. He trained in paediatrics at Guys Hospital, London; Hospital for Sick Children, Great Ormond Street, London and St Luke University Hospital, Brussels, Belgium. He undertook a PhD with Sir Brian Greenwood at the London School of Hygiene and Tropical Medicine Hygiene on the chemoprevention of anaemia. He is vice-president of The Gambian Chapter of the West African College of Physicians and a fellow of the Royal College of Physicians, UK. Since January 2011, he has been seconded to University of The Gambia to head of the paediatric department of the Royal Victoria Teaching Hospital. He is a member of the WHO IVR/Global Malaria Programme Joint Technical Expert Group (JTEG) on Malaria Vaccines Entering Pivotal Phase 3 Trials.

Bill Brieger

William Brieger is Professor in the Health Systems Program of the Department of International Health at The Johns Hopkins Bloomberg School of Public Health and also serves as JHPIEGO’s Senior Malaria Specialist. William is a Certified Health Education Specialist and has a Doctorate in Public Health (DrPH) in international health from the Johns Hopkins University (JHU) and a Masters in Public Health (MPH) from the University of North Carolina, Chapel Hill. Bill taught at the African Regional Health Education Center at the University of Ibadan, Nigeria, from 1976 to 2002. He is internationally renowned for his expertise in the social and behavioral aspects of tropical disease control and prevention, with special emphasis on malaria, onchocerciasis and guineaworm.

Muhwa Chakaya

Dr Muhwa Chakaya is Chief Research Officer and Consultant Chest Physician at Kenya Medical Research Institute.

Moupali Das

Moupali Das is Assistant Clinical Professor the University of California, San Francisco.

Steven G Deeks

Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Positive Health Program (AIDS Program) at San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is an expert on the role of chronic inflammation in untreated and treated HIV disease. His research has several linked objectives, including: (1) to determine the mechanisms which contribute to this persistent inflammation during therapy, (2) to characterize the impact of persistent inflammation during antiretroviral therapy on end-organ disease and function, (3) to determine the impact of inflammation and immune dysfunction on HIV persistence during effective therapy and (4) to develop novel therapeutic interventions which reduce chronic inflammation and/or the size of the latent reservoir.

Thom Eisele

Thom Eisele is an Associate Professor at the Tulane School of Public Health and Tropical Medicine and the Director of the Center for Applied Malaria Research and Evaluation. His research focuses on malaria epidemiology and evaluating malaria control and elimination strategies. Areas of expertise include malaria epidemiology, evaluating the impact of malaria control/elimination strategies, and measurement of malaria intervention coverage and malaria health outcomes. His current research focuses on measuring the impact of focal mass drug administration aimed at eliminating malaria in Southern Province Zambia through a collaborates with the Malaria Control and Evaluation Partnership in Africa (MACEPA) with funding from Bill and Melinda Gates Foundation. Dr. Eisele is a member of the Roll Back Malaria Monitoring and Evaluation Reference Group, the Technical Expert Group on Surveillance, Monitoring and Evaluation for the WHO Global Malaria Program, and was previously a Malaria Expert Group member of the WHO Child Health Epidemiology Reference Group.

Jerrold J Ellner

Jerrold J. Ellner, MD, has been appointed chief of the section of infectious diseases at Boston Medical Center and professor of medicine in the department of medicine at Boston University School of Medicine. Ellner previously had served as chair of the department of medicine at the New Jersey Medical School of the University of Medicine and Dentistry of New Jersey from 2002 to 2006, and was most recently professor of medicine and scientific director of the Center for Emerging Pathogens at UMDNJ. Ellner joined the faculty at Case Western Reserve University as an assistant professor in 1976 and was promoted to professor of medicine and pathology in 1983. He served as chief of the division of infectious diseases at Case Western Reserve University and University Hospitals of Cleveland from 1979 through 1996. Ellner also served as vice-chair, executive vice chair and interim chair of the department of medicine at Case Western Reserve University. He was director of the Tuberculosis Research Unit at Case Western Reserve University from 1994 through 1999.

Monica Gandhi

Monica Gandhi MD, MPH is Professor of Medicine in the Division of HIV/AIDS and has served as medical (clinic) director of the Positive Health Program (“Ward 86”) since January 2014. Dr. Gandhi completed her M.D. at Harvard Medical School and then came to UCSF in 1996 for residency training in Internal Medicine. After her residency, Dr. Gandhi completed a fellowship in Infectious Diseases and a postdoctoral fellowship at the Center for AIDS Prevention Studies, both at UCSF. She also obtained a Masters in Public Health from Berkeley in 2001 with a focus on Epidemiology and Biostatistics. Dr. Gandhi directs the AIDS Consult Service at San Francisco General Hospital (SFGH) and attends on the inpatient Infectious Diseases consult service. Dr. Gandhi also has an interest at UCSF in HIV education and mentorship.

Christopher Gilpin

Dr Christopher Gilpin is Scientist in the TB Diagnostics and Laboratory Strengthening Unit (TBL) of the Global TB Programme. He has over twenty years experience as a Microbiology Laboratory Scientist managing diagnostic laboratories in Australia and the Middle-East.

Philippe Glaziou

Dr Philippe Glaziou is Senior Epidemiologist at the World Health Organization. He leads the epidemiology sub-team of the Global TB Programme at WHO Headquarters in Geneva since 2008. Prior to joining the WHO in 2004 at the Regional Office for the Western Pacific (Manila, Philippines), he has worked with Institute Pasteur (Paris, France) in the capacity of clinical research laboratory head and has been posted in different countries including Cambodia, Central African Republic and French Polynesia.

Malgosia Grzemska

Dr. Malgorzata Grzemska works in the WHO’s Global TB Programme in Geneva. She is responsible for coordinating technical assistance to regions and countries in implementing Stop TB Strategy, development of treatment policies on TB and Childhood TB. Dr Grzemska started her international career in 1994 when she joined WHO. She specialized in Pediatrics and obtained a PhD in 1989 and a public health specialty in 2004. Dr Grzemska is an author and co-author of several publications.

Davidson Hamer

Davidson Hamer, MD, FACP, FIDSA, is a Professor of International Health and Medicine at the Boston University School of Public Health and School of Medicine, and Adjunct Professor of Nutrition at the Tufts University Friedman School of Nutrition Science and Policy. Dr. Hamer is a board-certified specialist in infectious diseases, with a particular interest in tropical infectious diseases, and has twenty years of field experience in neonatal and child survival research including studies of micronutrient interventions, maternal and neonatal health, malaria, pneumonia, and diarrheal diseases. During the last 15+ years, he has supervised and provided technical support to more than 50 studies in developing countries that evaluated interventions for improving neonatal survival, treatment and prevention of malaria, HIV/AIDS, micronutrient deficiencies, diarrheal disease, and pneumonia. He currently has active projects in Zambia, Tanzania, and Ecuador.

Brad Hare

Bradley Hare, MD is Associate Professor of Clinical Medicine and Medical Director, UCSF HIV/AIDS Division at San Francisco General Hospital. He conducts patient-based research on a variety of topics important to HIV clinical management, the inspiration for which comes directly from observations in the clinic. Current areas of focus include HIV and Hepatitis C Virus (HCV) co-infection, where he studies the epidemiology, natural history and treatment of acute hepatitis C infection, the use of novel agents in the treatment of HIV-HCV co-infection, and models of HCV treatment in primary care settings. He also conducts research on HIV testing in medical settings such as the Emergency Department, linkage to care after HIV testing, and implementation of a patient-centered medical home for people aging with HIV infection.

Anthony Harries

Anthony David Harries is an honorary professor at the London School of Hygiene and Tropical Medicine and Senior Advisor at The International Union Against Tubercuolsis and Lung Diseases. He is a physician and a registered specialist in the United Kingdom in infectious diseases and tropical medicine and spent over 20 years living and working in sub-Saharan Africa. In Malawi he served the Ministry of Health as National Advisor on both TB and HIV, with responsibility for scaling up antiretroviral therapy there. In 2008, he joined The Union, where he has launched a successful training programme in operational research, among other achievements. In 2002 Prof Harries was appointed Officer of the Order of the British Empire (OBE) for services to work in TB in Africa. He is also an honorary professor at the London School of Hygiene and Tropical Medicine and the author of hundreds of published papers on TB, HIV/AIDS, tropical medicine and the impact of operational research.

Diane V Havlir

Diane Havlir, MD, is chief of the HIV/AIDS division and Positive Health Program at San Francisco General Hospital and professor of medicine at the University of California, San Francisco. Diane was a physician in training when the AIDS epidemic emerged in the 1980s and has cared for HIV-infected patients in the clinic and hospital ever since. She has conducted clinical research in HIV and co-infections for over 25 years, with over 200 publications. Dr. Havlir conducted the first pivotal study showing the protective effect of azithromycin against M. avium infections for persons with AIDS, numerous studies on antiretroviral therapy and drug resistance, and a recent international study demonstrating the beneficial effect of starting antiretroviral therapy early in persons with HIV and tuberculosis. She is currently leading a community randomized study in East Africa (SEARCH) measuring the health, economic, and education effects of testing and treating all HIV-infected persons.

Ajay Kumar

Dr Ajay Kumar currently works as the Deputy Director (Center for Operational Research) of the International Union Against Tuberculosis and Lung Disease and also leads the operational research initiatives of the South-East Asia Regional office. He is actively involved in conducting and publishing operational research in TB, HIV and Diabetes Mellitus. He organizes and facilitates many international and national courses on operational research and mentors young researchers across the globe (India, Asia, Africa, Europe and South Pacific).

Jay A. Levy

Jay A. Levy, MD, is professor in the Department of Medicine and research associate in the Cancer Research Institute at UCSF. He is director of the Laboratory for Tumor and AIDS Virus Research at UCSF. In his early work, Dr. Levy discovered xenotropic viruses that introduced a new paradigm in virology. During the past 30 years, Dr. Levy and his staff have dedicated their efforts to research on AIDS. In 1983 he independently discovered the AIDS virus, HIV, which he originally called the AIDS-associated retrovirus (ARV). He pioneered heat-treatment studies that demonstrated how to heat-inactivate HIV in clotting factor preparations. Dr. Levy is a fellow of the American Academy of Arts and Sciences, American Association for the Advancement of Science, and the American Academy of Microbiology. He was given the Award of Distinction by the American Foundation for AIDS Research (AmFAR).

Annie Luetkemeyer

Dr Luetkemeyer is an assistant professor of medicine at University of California San Francisco (UCSF) and an attending physician at San Francisco General Hospital (SFGH) where she specializes in HIV/AIDS. Her clinical responsibilities include outpatient services at the San Francisco General Hospital HIV clinic as well as inpatient services on the HIV/AIDS, general medicine, and infectious diseases consult services. Dr Luetkemeyer directs the HIV Clinical Trials Group at SFGH, which conducts investigator-initiated and industry HIV trials. She is a site investigator for the Adult AIDS Clinical Trials Group (ACTG). Her research interests include HIV and tuberculosis coinfection, development of novel tuberculosis diagnostics, and HIV and viral hepatitis coinfection.

Alan Magill

Dr. Alan Magill oversees the development and implementation of strategies for the Gates foundation’s ultimate goal of the eradication of malaria using current tools and strategies as well as developing new generations of vaccines, diagnostics, and anti-malarial therapies to be used in novel and innovative ways.

Before joining the Global Health Program in 2012, Dr. Magill worked at the Defense Advanced Research Program Agency (DARPA), and was responsible for accelerating program development for their pandemic influenza initiative. Dr. Magill has also served as Head of Parasitology at the US Navy’s Medical Research Center in Peru and has lived in Germany, where he was a clinician.

Dr. Magill is board-certified in internal medicine with a subspecialization in infectious disease. He graduated with a Bachelor’s degree from Lamar University, has a Master of Science from the University of Rhode Island and an MD from Baylor University. He completed his residency at the Tripler Army Medical Center in Hawaii, the headquarters of the Pacific Regional Medical Command.

Kevin Marsh

Kevin Marsh is Professor of Tropical Medicine at Oxford University, Nuffield Department of Medicine. He is also the Director of the KEMRI Wellcome Trust Research Programme, chair of the Oxford Tropical Network and chair of the WHO Malaria Policy Advisory Committee recently established to advise the Director general of the WHO on malaria.

Helen McShane

Helen McShane is Professor of Vaccinology at Oxford University, Nuffield Department of Medicine. She leads the TB vaccine programme at Oxford University and is working on a BCG challenge model. MVA85A, the original new TB vaccine developed at Oxford and made by Dr McShane during her PhD, was the first new TB vaccine to enter into clinical trials in 2002.

Giovanni B Migliori

Giovanni B Migliori is Director of the WHO Collaboration Centre for Lung Diseases.

Edward A Nardell

Dr. Nardell is an associate professor in the Departments of Medicine and of Global Health and Social Medicine at Harvard Medical School and in the Departments of Immunology and Infectious Diseases and of Environmental Health at the Harvard School of Public Health. He is an associate in medicine in the Department of Medicine at Brigham and Women’s Hospital (BWH), in both the Division of Global Health Equity and the Pulmonary Division. His research interests involve the control of tuberculosis under resource-limited conditions, with a focus on the pathogenesis of drug-resistant tuberculosis, its airborne transmission, and transmission control in institutions.

Robert D Newman

Dr. Robert D. Newman is a pediatrician and is currently the Managing Director for Policy and Performance at the GAVI Alliance Secretariat in Geneva, Switzerland. He oversees organizational strategy setting, market shaping, policy development, business planning, and monitoring & evaluation. Before joining GAVI, Dr. Newman was Director of the Global Malaria Programme at the World Health Organization (WHO) in Geneva from 2009 to 2014. Previously, he was Deputy Chief for Science and Chief of the Program Implementation Unit in the Malaria Branch at the Centers for Disease Control and Prevention (CDC). He also served as the CDC Team Lead for the President’s Malaria Initiative (PMI), directing a staff of more than 45 public health professionals in Atlanta and 15 African countries. During the past decade, Dr. Newman has been dedicated to advancing the science of preventing malaria during pregnancy and infancy in sub-Saharan Africa, and served as the principal investigator for numerous epidemiological studies and clinical trials. From 1998-2000, Dr. Newman was Mozambique Country Coordinator for Health Alliance International, a non-governmental organization working on maternal-child health.

Francois Nosten

Francois Nosten is Professor in Tropical Medicine at Oxford University, Nuffield Department of Medicine. He is also the Director of the Shoklo Malaria Research Unit in Thailand. His work concentrates on malaria and he has conducted the largest ever drug trials in malaria in an area which has the world’s most drug-resistant parasites, including a detailed study of the SPf66 malaria vaccine. Recent studies have concentrated on the efficacy and effectiveness of combinations anti malarial therapy. Dr Nosten has also investigated malaria prophylaxis and antimalarial treatment in pregnancy and the identification of thiamine deficiency (beri-beri) as a major cause of infant mortality amongst Karen refugees. His team is now leading the efforts to eliminate artemisinin resistant P.falciparum from eastern Myanmar. SMRU is also involved in the treatment of tuberculosis in the population living on the Thai-Myanmar border.

Mario Raviglione

Dr Mario C. Raviglione has been Director of the Global TB Programme at the World Health Organization (WHO) since 2003. He joined WHO in 1991 to work on TB/HIV research and TB epidemiology in Europe. He contributed to the development of the DOTS strategy in 1994, and set up the global drug-resistance surveillance project (1994) and the global TB surveillance & monitoring system (1995).

Mario Raviglione has published over 250 articles and chapters on the topics of infectious diseases, HIV/AIDS and TB in the most influential health journals and books, including in the last five editions of the prestigious Harrison’s Principles of Internal Medicine. He is among the top 10 most cited authors in the TB field. He is editor of the 3rd and 4th (2006, 2009) edition of “Tuberculosis – A comprehensive International Approach”, a landmark multi-author book, and associate editor of other books.

Neil W Schluger

Neil W. Schluger, M.D. is the Chief of the Division of Pulmonary, Allergy and Critical Care Medicine at the Columbia University Medical Center and Professor of Medicine, Epidemiology and Environmental Health Science at the Columbia University College of Physicians and Surgeons and Columbia’s Mailman School of Public Health. Dr. Schluger is also the Chief Scientific Officer of the World Lung Foundation. He is a graduate of Harvard College and the University of Pennsylvania School of Medicine, and took his training in pulmonary and critical care medicine at the Cornell University Medical Center in New York. He has served as a visiting fellow and guest investigator at the Rockefeller University and in the Pulmonary Branch of the National Hearth, Lung, and Blood Institute of NIH. Dr. Schluger is the author of over 100 articles, chapters and books, and his work has been published in The New England Journal of Medicine, JAMA, The Lancet, and the American Journal of Respiratory and Critical Care Medicine, among other journals. He also currently serves as the Chairman of the Steering Committee of the Tuberculosis Trials Consortium (TBTC), an international research consortium funded by the Centers for Disease Control and Prevention (CDC).

Elena Stylianou

Dr Elena Stylianou is a post-doctoral research scientist at the Jenner Institute, University of Oxford UK. She works in the group of Prof. Helen McShane, developing novel vaccines against TB. She has been working in the field of TB vaccines for the past 8 years.

Steve Taylor

Steve Taylor is an infectious diseases clinician and is transitioning to independence as a laboratory-based investigator in translational studies of falciparum malaria in children and pregnant women. He contributes to DGHI’s educational mission by delivering seminars, contributing to courses, and mentoring MScGH students interested in clinical or laboratory studies of malaria. From a research perspective, he anticipates designing projects with DGHI field partners in Eldoret, Kenya and enhancing nascent research efforts in Kigali, Rwanda. Finally, he maintains active collaborations with investigators working in more than a dozen African countries and hope to enhance their connections with Duke. He hopes to use malaria research as a tool to enhance educational and research products of Duke and investigators in malaria-endemic areas.

Nick White

Professor Nicholas White is Professor of Tropical Medicine at the Faculty of Tropical Medicine, Mahidol University and Oxford University, and is also a Consultant Physician at the John Radcliffe Hospital, Oxford, UK. He chairs the Wellcome Trust Tropical Medicine Research Programme in South-East Asia, and the Oxford Tropical Medicine Network (encompassing research groups in Thailand, Vietnam, Laos, Kenya and The Gambia). He also currently co-chairs the World Health Organisation antimalarial treatment guidelines committee and the WHO Global Malaria Programme case management cluster.

He is currently on the Editorial or Advisory Boards of 13 scientific journals including The Lancet, PLOS Medicine, the European Journal of Clinical Pharmacology and Antimicrobial Agents and Chemotherapy. He has published over 880 scientific papers and over 40 book chapters.